CClinicalTrials.gg
CompletedNCT07434323LAPAMUpdated Feb 25, 2026

Lavender Aromatherapy for Preoperative Anxiety in Melanoma and Epithelioma Patients

An interventional study of Lavender Essential Oil and Physiological saline solution (as placebo) in Melanoma, Non-Melanoma Skin Cancer and Preoperative Anxiety, sponsored by San Gallicano Dermatological Institute IRCCS. Completed at 1 site in Italy. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-02-25.

Sponsored by San Gallicano Dermatological Institute IRCCS · Not applicable, Interventional, and Supportive care

Phase
Not applicable
Study type
Interventional
Enrollment
66
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Study summary

This double-blind, randomized, placebo-controlled trial evaluates whether a single 15-minute session of inhalational lavender aromatherapy, administered preoperatively, reduces anxiety in adult patients (ASA I-II) scheduled for surgical radicalization of pT1a melanoma or epithelioma. Physiological parameters (blood pressure, heart rate, respiratory rate) and validated psychometric scales (DASS-21, STAI Y-1 and Y-2) will be recorded at defined time points before and after the intervention. Total planned enrollment: 66 participants

Read the detailed description

Patients admitted to the Plastic, Reconstructive and Regenerative Surgery Unit who meet inclusion criteria will be randomly assigned (1:1) to the experimental group (lavender essential oil inhalation for 15 minutes via dedicated diffuser) or to the placebo group (physiological saline inhalation for 15 minutes). Assessments occur at T0 (ward admission before aromatherapy), T1 (arrival in operating block after aromatherapy, before surgery), T2 (end of surgical procedure), T3 (48 hours post-surgery), and T4 (7 days post-surgery for complications). Primary psychometric assessments include STAI Y-1 and STAI Y-2; additional measures include DASS-21 and vital signs. Randomization is centralized and computer-generated; allocation is concealed. Estimated data collection period: approximately six months. Sample size: 33 subjects per arm (66 total).

02

Conditions studied

  • Melanoma
  • Non-Melanoma Skin Cancer
  • Preoperative Anxiety
  • pT1a

Browse trials for

Keywords

  • lavender
  • aromatherapy
  • preoperative anxiety
  • melanoma
  • non-melanoma skin cancer
  • randomized controlled trial
03

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Adults aged 18 to 80 years
  • Patients diagnosed with pT1a melanoma or non-melanoma skin cancer (epithelioma)
  • Scheduled for surgical radicalization under local anesthesia
  • American Society of Anesthesiologists (ASA) physical status classification I or II
  • Ability to understand and complete self-administered questionnaires (STAI Y-1, STAI Y-2, DASS-21)
  • Willingness and ability to provide written informed consent

Exclusion criteria

Exclusion Criteria

  • Known allergy or hypersensitivity to lavender or essential oils
  • Current use of anxiolytic, antidepressant, or psychotropic medications
  • History of psychiatric disorders or ongoing psychological treatment
  • Cognitive impairment or inability to complete questionnaires independently
  • Pregnancy or breastfeeding
  • Severe respiratory diseases (e.g., asthma, COPD) that could interfere with inhalational aromatherapy
  • ASA physical status classification ≥ III
  • Participation in another interventional clinical trial at the same time
04

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
66 participants (actual)

Study arms

  • Experimental
    Lavender aromatherapy

    Participants receive inhalational lavender essential oil aromatherapy for 15 minutes in the preoperative ward using a dedicated diffuser, prior to surgery for melanoma or non-melanoma skin cancer. Anxiety levels are assessed using validated psychometric scales and physiological parameters at predefined time points.

    Drug: Lavender Essential Oil

  • Placebo comparator
    Placebo (Physiological Saline)

    Participants receive inhalational physiological saline for 15 minutes in the preoperative ward using an identical diffuser, prior to surgery for melanoma or non-melanoma skin cancer. Anxiety levels are assessed using validated psychometric scales and physiological parameters at predefined time points.

    Drug: Physiological saline solution (as placebo)

Interventions

  • DrugLavender Essential Oil

    Patients will receive aromatherapy treatment based on lavender essential oil administered through a dedicated diffuser for 15 minutes prior to the surgical procedure. During administration, access to the room is restricted to maintain the concentration of active substances

    Also known as: Inhalational Aromatherapy

  • DrugPhysiological saline solution (as placebo)

    Patients will receive a placebo treatment consisting of a physiological saline solution administered through a dedicated diffuser for 15 minutes prior to surgery. This procedure mirrors the experimental group to maintain the study's double-blind integrity

    Also known as: Placebo Aromatherapy

05

What researchers measure

Primary outcomes

  1. Change in state anxiety score measured by the State-Trait Anxiety Inventory (STAI Form Y-1), score range 20-80 (higher scores indicate greater anxiety)

    Change in state anxiety score assessed using the State-Trait Anxiety Inventory, Form Y-1 (STAI Y-1), comparing baseline assessment prior to aromatherapy (T0) with assessment immediately after aromatherapy upon arrival in the operating block, before induction of anesthesia (T1).

    Time frame: From baseline (pre-intervention) to immediately after aromatherapy, upon arrival in the operating block, prior to induction of anesthesia.

Secondary outcomes

  1. Trait anxiety score measured by the State-Trait Anxiety Inventory (STAI Form Y-2), score range 20-80 (higher scores indicate greater anxiety)

    Trait anxiety score assessed using the State-Trait Anxiety Inventory, Form Y-2 (STAI Y-2), evaluated at baseline prior to aromatherapy.

    Time frame: Baseline (pre-intervention).

  2. Postoperative Anxiety Level

    Anxiety level assessed using the State-Trait Anxiety Inventory, Form Y-1 (STAI Y-1), after completion of the surgical procedure.

    Time frame: End of surgery (T2)

  3. Postoperative Complications

    Incidence of postoperative complications assessed through clinical evaluation.

    Time frame: From surgery completion up to 7 days postoperatively (T4)

  4. Change in systolic blood pressure (mmHg)

    Change in systolic blood pressure measured before and after aromatherapy

    Time frame: From baseline (pre-intervention) to immediately after aromatherapy, upon arrival in the operating block.

  5. Change in diastolic blood pressure (mmHg)

    Change in diastolic blood pressure measured before and after aromatherapy.

    Time frame: From baseline (pre-intervention) to immediately after aromatherapy, upon arrival in the operating block.

  6. Change in heart rate (beats per minute)

    Change in heart rate measured before and after aromatherapy.

    Time frame: From baseline (pre-intervention) to immediately after aromatherapy, upon arrival in the operating block.

06

Study locations

1 site
  • San Gallicano Dermatological Institute IRCCS
    Roma, Italy 00144, Italy
07

References and documents

Publications

  • Kao R, Wannemuehler T, Yates CW, Nelson RF. Outpatient management of cholesteatoma with canal wall reconstruction tympanomastoidectomy. Laryngoscope Investig Otolaryngol. 2017 Oct 31;2(6):351-357. doi: 10.1002/lio2.116. eCollection 2017 Dec. PubMed 29299507 ↗
  • Ishio J, Komasawa N, Kido H, Minami T. Difficult airway management using Pentax-AWS Airwayscope with pediatric Intlock and tracheal tube introducer in Goldenhar syndrome patient. J Clin Anesth. 2016 Sep;33:223-4. doi: 10.1016/j.jclinane.2016.03.069. Epub 2016 May 4. No abstract available. PubMed 27555169 ↗
  • Beyliklioglu A, Arslan S. Effect of Lavender Oil on the Anxiety of Patients Before Breast Surgery. J Perianesth Nurs. 2019 Jun;34(3):587-593. doi: 10.1016/j.jopan.2018.10.002. Epub 2019 Jan 16. PubMed 30660371 ↗
  • Yang EJ, Lipner SR. Differences in price trends between branded and generic medications for onychomycosis. Dermatol Ther. 2020 Nov;33(6):e13928. doi: 10.1111/dth.13928. Epub 2020 Jul 13. No abstract available. PubMed 32602157 ↗
  • Tofield A. Peace Plaque for the city of Barcelona. Eur Heart J. 2018 Feb 14;39(7):502. doi: 10.1093/eurheartj/ehy032. No abstract available. PubMed 29452414 ↗
  • Whichello C, Bywall KS, Mauer J, Stephen W, Cleemput I, Pinto CA, van Overbeeke E, Huys I, de Bekker-Grob EW, Hermann R, Veldwijk J. An overview of critical decision-points in the medical product lifecycle: Where to include patient preference information in the decision-making process? Health Policy. 2020 Dec;124(12):1325-1332. doi: 10.1016/j.healthpol.2020.07.007. Epub 2020 Jul 30. PubMed 32839011 ↗
  • Wainwright BJ, Zahn GL, Zushi J, Lee NLY, Ooi JLS, Lee JN, Huang D. Seagrass-associated fungal communities show distance decay of similarity that has implications for seagrass management and restoration. Ecol Evol. 2019 Sep 15;9(19):11288-11297. doi: 10.1002/ece3.5631. eCollection 2019 Oct. PubMed 31641473 ↗

Individual participant data

Plan to share: No — Individual participant data (IPD) will not be shared to ensure the confidentiality of patients' personal information. The results of the research will be owned by the UOSD Plastic Surgery ISG and the UOC Anaesthesia and Resuscitation. Findings will be disseminated exclusively through publications in specialized journals and presentations at national and international congresses

08

Registry details

Key details

Study ID
NCT07434323
Lead sponsor
San Gallicano Dermatological Institute IRCCS
Responsible party
Sponsor
First posted
Feb 25, 2026
Start date
Nov 2, 2021
Primary completion
Dec 16, 2021
Completion
Nov 2, 2024
Last update
Feb 25, 2026

Study contacts

Emilia Migliano, Phd
principal investigator · San Gallicano Dermatological Institute IRCCS

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion